Portfolio

Problem solver and creative thinker. Extremely confident Studio Manager with more than 15 years
experience in the graphic industry. Superb Print and Digital Production, Creative Development,
New Business Development, and Presentation knowledge. Managing for over 10 years, Ernie Arias
has learned that every studio has its own personality and for that reason it needs its own customized
directives, based on industry standard procedures to be able to function and engage seamlessly with
the rest of the agency. He also possesses the ability to train, coach and manage a team of studio
artists, moving everyone up to the next level, especially when upgrading equipment and software, or
instructing a new process. Hes a big fan of procedures and technology, yet his main focus is always
on the business biggest asset, the human resources.

Ernie Arias, Studio Manager

at Hogarth Worldwide

As a Studio Manager, Ernie has worked with major leading global brands with high volume print
and digital production workflow: Luxury & Beauty: Diamond Trading Company (DTC), Rolex,
Este Lauder, Energizer, Revlon, Unilever; Beverages: Smirnoff, Cuervo, Beringer, Heineken, Tecate,
Dos XX; Technology & Telecom: Microsoft Bing, Nokia, Google, Vonage; Banking & Financial: HSBC,
T. Rowe Price, KPMG, Merril Lynch, Bank of America; Health Care: Johnson & Johnson, Pfizer,
Bristol Myers Squibb, AstraZeneca, Sunovion, Janssen, Bayer, Food: Nestl, Special K, Kraft;
Auto Industry: Ford; Apparel & Retail: LL Bean, Puma, and Macys.

Portfolio
B:16
T:15.75
S:15

For Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

IF YOU HAVE A TYPE OF

ADVANCED-STAGE LUNG CANCER,
THIS IS BIG.

OPDIVO is the first and only immunotherapy the FDA approved based on two clinical trials that demonstrated
longer life for adults with advanced NSCLC previously treated with platinum-based chemotherapy
OPDIVO works with your immune system
OPDIVO significantly increased the chance of living longer vs chemotherapy (docetaxel)
OPDIVO was studied in adults with advanced NSCLC previously treated with platinum-based chemotherapy:
Trial 1 (Squamous): 135 were treated with OPDIVO and 137 were treated with chemotherapy (docetaxel). OPDIVO
reduced the risk of dying by 41% compared to chemotherapy (docetaxel). Half of the patients on OPDIVO were still
alive at 9.2 months, compared to 6 months with chemotherapy (docetaxel).
Trial 2 (Non-squamous): 292 were treated with OPDIVO and 290 were treated with chemotherapy (docetaxel).
OPDIVO reduced the risk of dying by 27% compared to chemotherapy (docetaxel). Half of the patients on OPDIVO
were still alive at 12.2 months, compared to 9.4 months with chemotherapy (docetaxel). Additionally, OPDIVO was
shown to partially or completely shrink tumors in 19% of patients, compared to 12% with chemotherapy (docetaxel).
There was no difference between the two treatments in the length of time that patients lived without their
tumors worsening.
OPDIVO will not work for every patient. Individual results may vary.

Talk to your doctor today about OPDIVO.

of OPDIVO. For more information, ask your healthcare provider

or pharmacist.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch
or call 1-800-FDA-1088.

Please see Important Facts

for OPDIVO on the following page.

Print Production

Digital Production
Expect More.

Please visit www.OPDIVO.com/time or call 1-855-OPDIVO-1 for more information.

2015 Bristol-Myers Squibb Company. All rights reserved.

OPDIVO and the related logo are trademarks of Bristol-Myers Squibb Company. Printed in USA. 1506US1502316-01-01 10/15

F:7.875

F:7.875

90884-50

Transmission#:
Client: Bristol-Myers Squibb
Brand: Opdivo

Print Production Job Name: Opdivo Projections 057

Suburban Submission PDF

JWT #: 1117877
Campaign: BMS Oncology Campaign
Launch
Proof: 1 Page: 1

FILE: 90884_50_M_Projections_057_TIME_Urban_
M1.indd
Transmission Artist: EARIAS
Safety: 15 x 10
Trim: 15.75 x 10.5
Bleed: 16 x 10.75
Gutter: 0

Pub Date:None
Publication:None
Ad#: None

DOC PATH: JWLN_Projects:Volumes:JWLN_Projects:Bristol_Myers_Squibb:90884:Docs:90884_50_M_Projections_057_TIME_Urban_M1.indd

IMAGES:

PP: David Allen

PM: Tony Depietro
AD: Peter Ikrath
ECD: None
CD: Scott Lewis
CW: None
AE: Alison Loiacono

S:10

Important Safety Information

OPDIVO (nivolumab) is a medicine that may treat your lung cancer

by working with your immune system. OPDIVO can cause your
immune system to attack normal organs and tissues in many areas
of your body and can affect the way they work. These problems can
sometimes become serious or life-threatening and can lead to death.
These problems may happen anytime during treatment or even after
your treatment has ended.
Call or see your healthcare provider right away if you develop
any symptoms of the following problems or these symptoms get
worse.
Serious side effects may include:
n Lung problems (pneumonitis). Symptoms of pneumonitis
may include: new or worsening cough; chest pain; and shortness
of breath.
n Intestinal problems (colitis) that can lead to tears or holes
in your intestine. Signs and symptoms of colitis may include:
diarrhea (loose stools) or more bowel movements than usual;
blood in your stools or dark, tarry, sticky stools; and severe
stomach area (abdomen) pain or tenderness.

Pregnancy and Nursing:

Tell your healthcare provider if you are pregnant or plan to become
pregnant. OPDIVO can harm your unborn baby. Females who are able
to become pregnant should use an effective method of birth control
during and for at least 5 months after the last dose of OPDIVO.
Talk to your doctor about birth control methods that you can use
during this time. Tell your doctor right away if you become pregnant
during treatment with OPDIVO. Before receiving OPDIVO, tell your
healthcare provider if you are breastfeeding or plan to breastfeed.
It is not known if OPDIVO passes into your breast milk. Do not
breastfeed during treatment with OPDIVO.
Tell your healthcare provider about:
n Your health problems or concerns if you: have immune system
problems such as Crohns disease, ulcerative colitis, or lupus; have
had an organ transplant; have lung or breathing problems; have
liver problems; or have any other medical conditions
n All the medicines you take, including prescription and
over-the-counter medicines, vitamins, and herbal supplements
OPDIVO can cause severe infusion reactions. Tell your doctor or
nurse right away if you get these symptoms during an infusion
of OPDIVO: chills or shaking; itching or rash; flushing; difficulty
breathing; dizziness; fever; and feeling like passing out.
The most common side effects of OPDIVO in people with non-small
cell lung cancer include: feeling tired; pain in muscles, bones, and
joints; decreased appetite; cough; constipation; shortness of breath;
and nausea.
Tell your doctor if you have any side effect that bothers you or
that does not go away. These are not all the possible side effects

T:10.5

Creative Services
Management

Liver problems (hepatitis). Signs and symptoms of hepatitis may

include: yellowing of your skin or the whites of your eyes; severe
nausea or vomiting; pain on the right side of your stomach area
(abdomen); drowsiness; dark urine (tea colored); bleeding
or bruising more easily than normal; and feeling less hungry
than usual.
n Hormone gland problems (especially the thyroid, pituitary, and
adrenal glands). Signs and symptoms that your hormone glands
are not working properly may include: headaches that will not go
away or unusual headaches; extreme tiredness, weight gain or
weight loss; dizziness or fainting; changes in mood or behavior,
such as decreased sex drive, irritability, or forgetfulness; hair loss;
feeling cold; constipation; and voice gets deeper.
n Kidney problems, including nephritis and kidney failure. Signs
of kidney problems may include: decrease in the amount of urine;
blood in your urine; swelling in your ankles; and loss of appetite.
n Inflammation of the brain (encephalitis). Signs and symptoms of
encephalitis may include: headache; fever; tiredness or weakness;
confusion; memory problems; sleepiness; seeing or hearing things
that are not really there (hallucinations); seizures; and stiff neck.
n Problems in other organs. Signs of these problems may include:
rash; changes in eyesight; severe or persistent muscle or joint
pains; and severe muscle weakness.
Getting medical treatment right away may keep these problems
from becoming more serious.
Your doctor will check you for these problems during treatment with
OPDIVO. Your doctor may treat you with corticosteroid or hormone
replacement medicines and delay or completely stop treatment with
OPDIVO, if you have severe side effects.
n

OPDIVO (injection for intravenous use 10 mg/mL) is a prescription

medicine used to treat a type of advanced stage lung cancer
(non-small cell lung cancer) that has spread or grown and you have
tried chemotherapy that contains platinum, and it did not work or
is no longer working. If your tumor has an abnormal EGFR or ALK
gene, you should have also tried an FDA-approved therapy for
tumors with these abnormal genes, and it did not work or is no
longer working. It is not known if OPDIVO is safe and effective in
children less than 18 years of age.

B:10.75

What does OPDIVO treat?

INKS:
Saved: 10-16-2015 7:37 PM
Cyan
Printed: 10-16-2015 7:37 PM
Magenta
Print Scale: None
Yellow
Printer: Xerox Fiery EX260 Color
Black
Pantone 302
Server PS (3)
PMS 302 C
Media: Print
DENSITY: None
Type: Magazine
Vendor: None

Portfolio
Creative Services Management

Overseeing any studio operation requires a unique set of skills that involves a multi-disciplinary spectrum, and goes beyond the usual Adobe Creative
Suite expertise. You must be an expert in your field to be able to scrutinize the work you are overseeing; energetic, financially savvy, creative, excellent
communication skills, a negotiator (conflict management), a problem solver, and a bit of IT wizard to troubleshoot equipment and software on a
daily basisnothing short of Badass.
These are some of the main areas of our daily workload:

Communication
Meetings:
Status meetings
Staff meetings
Briefing
Kick-off
Post-mortem

Emails and
Phone calls
They are the core of
our daily communication
activities.

Financial and Operation

Management
Estimates
Forecasting
Cost-to-Date Reports
Downtime Reports
Time-Sheets
Rate Cards

Technology:
Research for the best tools out
there and recognize if its a
good fit for your organization.
Vision:
Based on experience, be able to
foresee potential problems of
any kind and prevent them.

Software Knowledge
Adobe Creative Suite
Photoshop
Illustrator
Indesign
Acrobat
Bridge
MS Office:
Word, Excel, and
PowerPoint
Workflow and DAM:
Xinet Webnative
Dalim Twist
JobCharge-FMP
FIDO and ZONZA (Hogarth)
IBM On-Demand
SmartSheet

Human Resources

Interviewing:
Able to conduct an effective
interview with a potential hire.
Performance Review:
Assess personnel
performance periodically.
Employee Engagement:
Create the environment
needed for employee growth.
Coaching and training new
skills, rolling out new technology (software, equipment) in
collaboration
with IT and/or DAM-Workflow
implementation managers.

Portfolio
Print Production

Print Production and Pre-press in the creation of ads, packaging, direct mail, and every kind of collateral pieces. Color and proofing
systems management, workflow, DAM, and file delivery system assisted with the most advanced technology in the industry. Robust Flightcheck and QC control to ensure files delivered to either a publisher or a vendor are up to the highest quality. Close collaboration with the
Creative Development and Retouching Managers, Print Producers and Studio Artists to streamline the workflow and guarantee budgets and
deadlines are met.

B:24.5
T:24

B:313 mm

S:23.75

B:15.25

B:16

T:15

T:300 mm

T:15.75
S:15

F:2
SCORE

For Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

IF YOU HAVE A TYPE OF

ADVANCED-STAGE LUNG CANCER,
THIS IS BIG.

T:4.776

TEXT MARDIGRAS TO 88474 FOR A CHANCE TO WIN A

PRINT OF THIS ORIGINAL ARTWORK SIGNED
BY ARTIST TERRANCE OSBORNE,
OR OTHER GREAT PRIZES.

OPDIVO is the first and only immunotherapy the FDA approved based on two clinical trials that demonstrated
longer life for adults with advanced NSCLC previously treated with platinum-based chemotherapy
OPDIVO works with your immune system
OPDIVO significantly increased the chance of living longer vs chemotherapy (docetaxel)
OPDIVO was studied in adults with advanced NSCLC previously treated with platinum-based chemotherapy:
Trial 1 (Squamous): 135 were treated with OPDIVO and 137 were treated with chemotherapy (docetaxel). OPDIVO
reduced the risk of dying by 41% compared to chemotherapy (docetaxel). Half of the patients on OPDIVO were still
alive at 9.2 months, compared to 6 months with chemotherapy (docetaxel).

95 calories
never tasted so good.

Trial 2 (Non-squamous): 292 were treated with OPDIVO and 290 were treated with chemotherapy (docetaxel).
OPDIVO reduced the risk of dying by 27% compared to chemotherapy (docetaxel). Half of the patients on OPDIVO
were still alive at 12.2 months, compared to 9.4 months with chemotherapy (docetaxel). Additionally, OPDIVO was
shown to partially or completely shrink tumors in 19% of patients, compared to 12% with chemotherapy (docetaxel).
There was no difference between the two treatments in the length of time that patients lived without their
tumors worsening.

CONFIDENCE IS KNOWING OUR INVESTMENT APPROACH STANDS THE TEST OF TIME

OPDIVO will not work for every patient. Individual results may vary.

Talk to your doctor today about OPDIVO.

F:15

PAGE

91022_1M_15187_Amstel_Burger_Ad_M3.indd
CMYK

Issued by T. Rowe Price International Ltd, 60 Queen Victoria Street, London EC4N 4TZ, which is authorised and regulated by the UK Financial Conduct Authority (the FCA). This material is not intended for use by Retail Clients, as defined
by the FCA. T. Rowe Price, Invest With Confidence, and the bighorn sheep logo are registered trademarks of T. Rowe Price Group, Inc. in the United Kingdom and other countries. This material was produced in the United Kingdom.

91156-1.1

PM
PRD

FONTS
QC
ST

Pub Date:None
Publication:None
Ad#: None

PP: None
PM: None
AD: None
ECD: None
CD: None
CW: None
AE: None

Saved: 9-11-2015 12:25 PM

Printed: 9-11-2015 12:25 PM
Print Scale: None
Printer: Costello
Media: Print
Type: Collateral
Vendor: None

INKS:
Cyan
Magenta
Yellow
Black

www.DOSEQUIS.com

91453_1_O_15173_Mardi-Gras_KV_M3.indd

JOB #
Heineken
CLIENT
BRAND
RETAILER
CREATED 11/17/15
OPERATOR EARIAS
MODIFIED 11/20/15
OPERATOR Marcel Thompkins
ROUND 3
15173

91453-1.1

Transmission#:
Client: Geometry
Brand: Heineken

Print Production Job Name: Mardi Gras KV

JWT #: 15173
Campaign: 2015 CE MARDI GRAS
EXECUTION
Proof: 3 Page: 1

ELEMENT:
23.75 x 35.75
LIVE
24 x 36
TRIM
24.5 x 36.5
BLEED
REFERENCE
DIE #
FOLD
100%
BUILT %
PRINT %

PAGE

Suburban Submission PDF

JWT #: 1117877
Campaign: BMS Oncology Campaign
Launch
Proof: 1 Page: 1

APPROVALS

FILE NAME

ACT
CRE
PM
PRD

FONTS

QC
ST

FILE: 91453_1_O_15173_Mardi-Gras_KV_M3.indd
Transmission Artist: Marcel Thompkins
Safety: 23.75 x 35.75
Trim: 24 x 36
Bleed: 24.5 x 36.5
Gutter: None

SKU
PROJ. TYPE

LINKS

CMYK

Pub Date: NA
Publication: NA
Ad#: NA

PP: John Marino

PM: NA
AD: NA
ECD: NA
CD: NA
CW: NA
AE: NA

INKS:
Saved: 11-20-2015 4:11 PM
Cyan
Printed: 11-20-2015 4:09 PM
Magenta
Print Scale: 39.58%
Yellow
Printer: Xerox Fiery EX260 Color
Black
DENSITY: 300
Server PS (3)
Media: Print
Type: OOH
Vendor: None

DOC PATH: JWLN_Projects:Volumes:JWLN_Projects:Geometry:91453:Docs:91453_1_O_15173_Mardi-Gras_KV_M3.indd

IMAGES:
PP_Slug.pdf 100% Up to Date JWLN_Projects:_Slug:PP_Slug.pdf
91453_Mardi_Gras_2016_SW300_02.psd
CMYK
400 ppi
99.99%
Up to Date
JWLN_Projects:Geometry:_Master_Art:Multiple_Brands:91453_Mardi_Gras:91453_Mardi_Gras_2016_SW300_02.psd
Heineken_OYW_Logo_White_SW300_01.ai
101.46%
Up to Date
JWLN_Projects:Geometry:_Logos:Heineken:Heineken_open_you_world:Heineken_OYW_Logo_White_SW300_01.ai
e_responsibility_2015_white_SW300_01.ai
100.16%
Up to Date
JWLN_Projects:Geometry:_Logos:Heineken:e_responsibility:e_responsibility_2015_white_SW300_01.ai
Enjoy_XX_Responsibly_white.ai 105.19%
Up to Date
JWLN_Projects:Geometry:_Logos:Dos_Equis:Enjoy_XX_Responsibly:Enjoy_XX_Responsibly_white.ai
FONTS:
ITC Franklin Gothic Medium Condensed, Book Condensed
Type 1
TT Slug OTF Regular, Bold
OpenType
Helvetica Neue 57 Condensed, 77 Bold Condensed Type 1
Futura Medium Condensed, Bold Condensed
Type 1
Futura Std Bold Condensed
OpenType

INK DENSITY: None

90884-50

Transmission#:
Client: Bristol-Myers Squibb
Brand: Opdivo

Print Production Job Name: Opdivo Projections 057

NO PURCHASE OR TEXT MESSAGE NECESSARY TO ENTER OR WIN. PURCHASING A PRODUCT OR SENDING A TEXT MESSAGE WILL NOT IMPROVE YOUR CHANCES OF WINNING. SWEEPSTAKES IS OPEN ONLY TO LEGAL RESIDENTS OF THE U.S. RESIDING IN THE STATE OF LOUISIANA WHO ARE 21 OR OLDER AS OF DATE OF ENTRY. SWEEPSTAKES IS GOVERNED EXCLUSIVELY BY THE LAWS OF THE UNITED STATES. Sweepstakes begins
at 12:01 a.m. Central Time (CT) on 1/1/16 and ends at 11:59 p.m. CT on 2/9/16. To enter, text MARDIGRAS to 88474 from your mobile device. Upon receiving a verification message, enter your 8-digit date of birth and the state code for your state of residence (e.g., MM/DD/YYYY-LA). Carriers standard messaging and data rates apply. OR to enter for free, for full terms and conditions, and for prize description, visit www.HeinekenMardiGras.com.
Sponsor: HEINEKEN USA Inc., New York, NY.

FILE NAME

91022_1M_15187_Amstel_Burger_Ad_M3.pgs SO5 X1a

09.11.2015 12:19

2015 CERVEZAS MEXICANAS, NEW YORK, NY

DE152497

Brewed
Holland. Lager
Imported
HEINEKEN
Inc.,
New
York, NY.
2015
HEINEKEN
Lager
Beer.
2016inHEINEKEN
Beer. by
HEINEKEN
LightUSA
Lager
Beer.
HEINEKEN
USA
Inc., New
York, NY. DOS
EQUIS
XX Special Lager Beer. Cervezas Mexicanas, New York, NY.

91083_1O_15154_Guacamole_Tuck_Card_M3.indd

15154
JOB #
Dos Equis
CLIENT
BRAND
RETAILER
CREATED 9/22/15
OPERATOR Laura Stout
MODIFIED 9/25/15
OPERATOR
ROUND 3

91083-1

Transmission#:
Client: Geometry
Brand: Dos Equis
Job Name: Guacamole Tuck Card
JWT #: 15154
Campaign: None
Proof: 3 Page: 1

ELEMENT:
LIVE
15 x 17
TRIM
15.25 x 17.25
BLEED
REFERENCE PSD file
DIE #
FOLD
BUILT %
PRINT %

CMYK

PAGE

LINKS

APPROVALS
ACT
CRE
PM

FONTS

FILE: 91083_1O_15154_Guacamole_Tuck_Card_M3.indd PP: None

PM: None
Transmission Artist: L. Stout
AD: None
ECD: None
FINAL SIZE:
CD: None
Safety: 17 x 15
CW: None
Trim: 17 x 15
AE: None
Bleed: 17.25 x 15.25

SCALE: 1 = 1
SCALED SIZE:
Safety: None
Trim: 17 x 15
Bleed: 17.25 x 15.25

SKU
PROJ. TYPE

350 WEST MART CENTER DRIVE

SUITE 1212
CHICAGO, IL 60654

CRE

FILE: 91022_1M_15187_Amstel_Burger_Ad_M3.indd
SO5 Artist: Marcel Thompkins
Safety: None
Trim: 4.776 x 6.484
Bleed: None
Gutter: None

F:7.875

Transmission#:
Client: T. Rowe Price
Brand: None
Job Name: GIS Bonsai Banner 300x100
JWT #: 1119850
Campaign: GIS Bonsai Banners &
Bellyband
Proof: 1 Page: 1

APPROVALS
ACT

DOC PATH: Production:Volumes:Production:GEOMETRY:AMSTEL:91022_15187_AMSTEL_BURGER_AD:DOCS:91022_1M_15187_Amstel_Burger_Ad_M3.indd

IMAGES:
91022_Amstel_Burger_Ad_SW300_01.tif
CMYK
300 ppi
100%
Up to Date
Production:GEOMETRY:_MASTER_ART:AMSTEL:91022_Amstel_Burger_Ad_SW300_01.tif
FONTS:
ITC Franklin Gothic Medium Condensed, Book Condensed
Type 1
Serifa BdCn BT Bold True Type
Dolce Caffe Regular OpenType

*91022-1*

Equity and Fixed Income Expertise

Expect More.

SKU
PROJ. TYPE

LINKS

350 WEST MART CENTER DRIVE

SUITE 1212
CHICAGO, IL 60654

91022-1

SO5#:
Client: Geometry
Brand: Amstel
Job Name: Amstel Burger Ad
JWT #: 15187
Campaign: None
Proof: 3 Page: 1

ELEMENT:
LIVE
4.776 x 6.484 non-bleed
TRIM
BLEED
REFERENCE InDesign/PSD
DIE #
FOLD
BUILT %
PRINT %

350 WEST MART CENTER DRIVE

SUITE 1212
CHICAGO, IL 60654

15187
JOB #
Amstel
CLIENT
BRAND
RETAILER
CREATED 9/08/15
OPERATOR Laura Stout
MODIFIED 9/11/15
OPERATOR Marcel Thompkins
ROUND 3

Put our equity and fixed income expertise to work for you. www.troweprice.com/intermediaries

2015 AMSTEL USA, NEW YORK, NY WWW. fAcEBOOK.cOM/AMSTELLIGHT @AMSTELLIGHT AMSTELLIGHT.cOM

F:7.875

FILE NAME

At T. Rowe Price, its been our mission since 1937 to always act in the best interests of our clients. The markets may be complex, but
our investment approach is straightforward. We believe in teamwork, fundamental research and taking a long-term approach. So
in markets both good and bad, you can feel confident our investment approach stands the test of time.

Please visit www.OPDIVO.com/time or call 1-855-OPDIVO-1 for more information.

2015 Bristol-Myers Squibb Company. All rights reserved.

OPDIVO and the related logo are trademarks of Bristol-Myers Squibb Company. Printed in USA. 1506US1502316-01-01 10/15

ENJOY AMSTEL LIGHT RESPONSIBLY

of OPDIVO. For more information, ask your healthcare provider

or pharmacist.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch
or call 1-800-FDA-1088.

Please see Important Facts

for OPDIVO on the following page.

T:100 mm

Pregnancy and Nursing:

Tell your healthcare provider if you are pregnant or plan to become
pregnant. OPDIVO can harm your unborn baby. Females who are able
to become pregnant should use an effective method of birth control
during and for at least 5 months after the last dose of OPDIVO.
Talk to your doctor about birth control methods that you can use
during this time. Tell your doctor right away if you become pregnant
during treatment with OPDIVO. Before receiving OPDIVO, tell your
healthcare provider if you are breastfeeding or plan to breastfeed.
It is not known if OPDIVO passes into your breast milk. Do not
breastfeed during treatment with OPDIVO.
Tell your healthcare provider about:
n Your health problems or concerns if you: have immune system
problems such as Crohns disease, ulcerative colitis, or lupus; have
had an organ transplant; have lung or breathing problems; have
liver problems; or have any other medical conditions
n All the medicines you take, including prescription and
over-the-counter medicines, vitamins, and herbal supplements
OPDIVO can cause severe infusion reactions. Tell your doctor or
nurse right away if you get these symptoms during an infusion
of OPDIVO: chills or shaking; itching or rash; flushing; difficulty
breathing; dizziness; fever; and feeling like passing out.
The most common side effects of OPDIVO in people with non-small
cell lung cancer include: feeling tired; pain in muscles, bones, and
joints; decreased appetite; cough; constipation; shortness of breath;
and nausea.
Tell your doctor if you have any side effect that bothers you or
that does not go away. These are not all the possible side effects

PRD
QC
ST

Saved: 9-25-2015 10:54 AM

Printed: 9-25-2015 10:54 AM
Print Scale: None
Printer: Amber
Media: Print
Type: OOH
Vendor:None

INKS:
Cyan
Magenta
Yellow
Black
DENSITY: None

DOC PATH: JWLN_Projects:Volumes:JWLN_Projects:Geometry:91083:Docs:91083_1O_15154_Guacamole_Tuck_Card_M3.indd

IMAGES:
91083_NTL.15154_XXGuca_TC_CV-SW300_02.tif
CMYK
300 ppi
100%
JWLN_Projects:Geometry:_Master_Art:DOS_EQUIS:91083_Guacamole_Tuck_Card:91083_NTL.15154_XXGuca_TC_CV-SW300_02.tif
91003_flourish.ai 43.47%
JWLN_Projects:Geometry:_MASTER_ART:DOS_EQUIS:91083_Guacamole_Tuck_Card:91003_flourish.ai
Stay_Thirsty_black_SW300_01.ai 11.23%
JWLN_Projects:Geometry:_LOGOS:DOS_EQUIS:Stay_Thirsty_my_friends:Stay_Thirsty_black_SW300_01.ai
Enjoy_XX_Responsibly__Helv_Neue_black_SW300_01.ai
141.65%
JWLN_Projects:Geometry:_LOGOS:DOS_EQUIS:Enjoy_XX_Responsibly:Enjoy_XX_Responsibly__Helv_Neue_black_SW300_01.ai
FONTS:
ITC Franklin Gothic Medium Condensed, Book Condensed
Type 1
TT Slug OTF Regular OpenType
Cochin Regular True Type
Caslon 540 LT Std Italic
OpenType
Helvetica Neue 67 Medium Condensed
Type 1

FILE: 90884_50_M_Projections_057_TIME_Urban_
M1.indd
Transmission Artist: EARIAS
Safety: 15 x 10
Trim: 15.75 x 10.5
Bleed: 16 x 10.75
Gutter: 0

Pub Date:None
Publication:None
Ad#: None

PP: David Allen

PM: Tony Depietro
AD: Peter Ikrath
ECD: None
CD: Scott Lewis
CW: None
AE: Alison Loiacono

INKS:
Saved: 10-16-2015 7:37 PM
Cyan
Printed: 10-16-2015 7:37 PM
Magenta
Print Scale: None
Yellow
Printer: Xerox Fiery EX260 Color
Black
Pantone 302
Server PS (3)
PMS 302 C
Media: Print
DENSITY: None
Type: Magazine
Vendor: None

DOC PATH: JWLN_Projects:Volumes:JWLN_Projects:Bristol_Myers_Squibb:90884:Docs:90884_50_M_Projections_057_TIME_Urban_M1.indd

IMAGES:
90334_OPDIVO_US_NA_Updated_BG_SW300_02.tif CMYK
434 ppi
103.67%
Up to Date
JWLN_Projects:Bristol_Myers_Squibb:_MASTER_ART:OPDIVO:90334_Living_Longer_Brochure:90334_OPDIVO_US_NA_Updated_BG_SW300_02.tif
OPDIVO_Island_Extended_4C copy.psd
CMYK
522 ppi
86.14%
Up to Date
JWLN_Projects:Bristol_Myers_Squibb:90884:SUPPLIED:OPDIVO_Print_BOR_017_08_18_15 Folder:Links:OPDIVO_Island_Extended_4C copy.psd
908545_PROJECTION_URBAN_SW300_09.tif
CMYK
375 ppi
79.93%
Up to Date
JWLN_Projects:Bristol_Myers_Squibb:90884:Supplied:057_Print_Urb_Sub_101515:90884_31_M_Projections_057_SUBMISSION_
Urban_101515 Folder:Links:908545_PROJECTION_URBAN_SW300_09.tif
051_BMS_Logo_cmyk.eps
72%
Up to Date
JWLN_Projects:Bristol_Myers_Squibb:_Logos:Bristol_Myers_Squibb:051_BMS_Logo_cmyk.eps
90334_EXCLAMATION_People_final_Ad_vers_SW300_01.psd
CMYK
1728 ppi
17.36%
Up to Date
JWLN_Projects:Bristol_Myers_Squibb:_Master_Art:Opdivo:90334_Living_Longer_Brochure:90334_EXCLAMATION_People_final_Ad_vers_SW300_01.psd
OPDIVO_US_TM_PROM_P_4C.eps 38.35%
Up to Date
JWLN_Projects:Bristol_Myers_Squibb:_Logos:Opdivo:Supplied_Logos_6242015:Trademark:OPDIVO_US_TM_PROM_P_4C.eps
FONTS:
Klavika Basic Bold, Light, Medium, Regular, Medium Italic
OpenType
Zapf Dingbats Regular
True Type
Klavika Regular OpenType

FILE: 91156_1_M_GIS_Bonsai_Banner_M1.indd
Transmission Artist: EARIAS
Safety: 287 mm x 87 mm
Trim: 300 mm x 100 mm
Bleed: 313 mm x 113 mm
Gutter: None

Pub Date: NA
Publication: NA
Ad#: NA

PP: Tiffan Hu
PM: NA
AD: Nick Canilang
ECD: NA
CD: NA
CW: Nate Goodson
AE: Hayden Sellers

Saved: 10-2-2015 4:27 PM

Printed: 10-2-2015 4:27 PM
Print Scale: None
Printer: None
Media: Print
Type: Please Choose
Vendor: None

INKS:
Cyan
Magenta
Yellow
Black
DENSITY: None

DOC PATH: JWLN_Projects:Volumes:JWLN_Projects:T_Rowe_Price:91156:Docs:91156_1_M_GIS_Bonsai_Banner_M1.indd

IMAGES:
89238_SHADOW_SW300_02.tif
CMYK
256 ppi, 439 ppi, 352 ppi, 613 ppi 174.63%, 101.9%, 126.96%, 72.97%
Up to Date
JWLN_Projects:T_Rowe_Price:91156:Supplied:BONSAI_300mmx100mm:Links:89238_SHADOW_SW300_02.tif
90722_BOOTS_BG_SW300_03.tif CMYK
360 ppi, 588 ppi 83.19%, 50.93% Up to Date
JWLN_Projects:T_Rowe_Price:_Master_Art:90722_Boots:90722_BOOTS_BG_SW300_03.tif
90386_TRP_BONSAI_TREEwithShadow_SW300_01.psd
CMYK
1574 ppi, -1575 ppi
19.05%, -19.05%
Up to Date
JWLN_Projects:T_Rowe_Price:_Master_Art:90386_Bonsai:90386_TRP_BONSAI_TREEwithShadow_SW300_01.psd
TRP_LogoDarkGray_CMYK.eps
47.32%
Up to Date
JWLN_Projects:T_Rowe_Price:_Logos:TRP_LogoDarkGray_CMYK.eps
TRP_SymbolBrightBlue_LightBG_R_CMYK.eps
41.52%
Up to Date
JWLN_Projects:T_Rowe_Price:_Logos:TRP_SymbolBrightBlue_LightBG_R_CMYK.eps
FONTS:
Nimbus Sans Novus Bold, Regular, Medium
OpenType

B:113 mm

Important Safety Information

OPDIVO (nivolumab) is a medicine that may treat your lung cancer

by working with your immune system. OPDIVO can cause your
immune system to attack normal organs and tissues in many areas
of your body and can affect the way they work. These problems can
sometimes become serious or life-threatening and can lead to death.
These problems may happen anytime during treatment or even after
your treatment has ended.
Call or see your healthcare provider right away if you develop
any symptoms of the following problems or these symptoms get
worse.
Serious side effects may include:
n Lung problems (pneumonitis). Symptoms of pneumonitis
may include: new or worsening cough; chest pain; and shortness
of breath.
n Intestinal problems (colitis) that can lead to tears or holes
in your intestine. Signs and symptoms of colitis may include:
diarrhea (loose stools) or more bowel movements than usual;
blood in your stools or dark, tarry, sticky stools; and severe
stomach area (abdomen) pain or tenderness.

S:10

T:17

SEE OFFER FOR DETAILS.

B:17.25

T:36

B:36.5

S:35.75

SAVE on DOS EQUIS and

FRESH GUACAMOLE.

Liver problems (hepatitis). Signs and symptoms of hepatitis may

include: yellowing of your skin or the whites of your eyes; severe
nausea or vomiting; pain on the right side of your stomach area
(abdomen); drowsiness; dark urine (tea colored); bleeding
or bruising more easily than normal; and feeling less hungry
than usual.
Hormone gland problems (especially the thyroid, pituitary, and
adrenal glands). Signs and symptoms that your hormone glands
are not working properly may include: headaches that will not go
away or unusual headaches; extreme tiredness, weight gain or
weight loss; dizziness or fainting; changes in mood or behavior,
such as decreased sex drive, irritability, or forgetfulness; hair loss;
feeling cold; constipation; and voice gets deeper.
n Kidney problems, including nephritis and kidney failure. Signs
of kidney problems may include: decrease in the amount of urine;
blood in your urine; swelling in your ankles; and loss of appetite.
n Inflammation of the brain (encephalitis). Signs and symptoms of
encephalitis may include: headache; fever; tiredness or weakness;
confusion; memory problems; sleepiness; seeing or hearing things
that are not really there (hallucinations); seizures; and stiff neck.
n Problems in other organs. Signs of these problems may include:
rash; changes in eyesight; severe or persistent muscle or joint
pains; and severe muscle weakness.
Getting medical treatment right away may keep these problems
from becoming more serious.
Your doctor will check you for these problems during treatment with
OPDIVO. Your doctor may treat you with corticosteroid or hormone
replacement medicines and delay or completely stop treatment with
OPDIVO, if you have severe side effects.
n

T:10.5

What does OPDIVO treat?

OPDIVO (injection for intravenous use 10 mg/mL) is a prescription

medicine used to treat a type of advanced stage lung cancer
(non-small cell lung cancer) that has spread or grown and you have
tried chemotherapy that contains platinum, and it did not work or
is no longer working. If your tumor has an abnormal EGFR or ALK
gene, you should have also tried an FDA-approved therapy for
tumors with these abnormal genes, and it did not work or is no
longer working. It is not known if OPDIVO is safe and effective in
children less than 18 years of age.

B:10.75

T:6.484

MAKE your NIGHT

MORE APPETIZING

Portfolio
Print Production
B:8.25

B:8.25

B:8.25

B:8.25

T:8

T:8

S:7.75

S:7.75

2015 Revlon

2015 Revlon

with Revlon Luxurious ColorSilk .

Ammonia-free formula with a triple butter complex,

now enriched with Argan oil and two times more conditioner
for superior color, conditioning and shine.

89981.2

SO5#:
Client: Revlon
Brand: None
Job Name: Print Ad - Full Page
JWT #: S515ADM
Campaign: Colorsilk Burgundy SP
Proof: 4 Page: 1

FILE: 89981_2M_CS_BURGUNDY_PAGE_AD_M4.indd
SO5 Artist: earias
Safety: 7.75 x 10.75
Trim: 8 x 11
Bleed: 8.25 x 11.25
Gutter: None

Pub Date: NA
Publication: NA
Ad#: NA

PP: Gina Bacile

PM: Ali Webb
AD: Juan Perez
ECD: NA
CD: NA
CW: NA
AE: NA

Saved: 3-24-2015 5:27 PM

Printed: 3-24-2015 5:27 PM
Print Scale: None
Printer: Abbott
Media: Print
Type: Magazine
Vendor: None

with Revlon ColorSilk .

with Revlon ColorSilk .

Ammonia-free formula with Revlon 3D Color Gel Technology

for multidimensional color that looks natural and lasts.

Ammonia-free formula with Revlon 3D Color Gel Technology

for multidimensional color that looks natural and lasts.

89981.1

INKS:
Cyan
Magenta
Yellow
Black

SO5#:
Client: Revlon
Brand: None
Job Name: Print Ad - Full Page
JWT #: S515ADM
Campaign: Colorsilk Blonde SP
Proof: 3 Page: 1

DOC PATH: Production:Volumes:Production:REVLON:89981_HAIR_COLOR_PRINT_ADS:DOCS:89981_2M_CS_BURGUNDY_PAGE_AD_M4.indd

IMAGES:
89981_LUXURIOUS_Burgundy_39_SW300_01.tif
CMYK
428 ppi
70%
Up to Date
Production:REVLON:_MASTER_ART:89981_HairColor:89981_LUXURIOUS_Burgundy_39_SW300_01.tif
LOVEISON_LOCKUP_ONWHITE_4c.ai
37.42%
Up to Date
Production:REVLON:_LOGOS:LOVEISON_LOCKUP_ONWHITE_4c.ai
89981_Packshots_LUXURIOUS_SW300_02.psd
CMYK
3082 ppi
9.73%
Up to Date
Production:REVLON:_MASTER_ART:89981_HairColor:89981_Packshots_LUXURIOUS_SW300_02.psd
FONTS:
Gotham Book, Black Type 1

*89981.2*

with Revlon Colorsilk.

Ammonia-free formula with 3D Color Gel Technology
for multidimensional color that looks natural and lasts.

FILE: 89981_1M_CS_BLONDE_PAGE_AD_M3.indd
SO5 Artist: Marcel A. Thompkins
Safety: 7.75 x 10.75
Trim: 8 x 11
Bleed: 8.25 x 11.25
Gutter: None

Pub Date: NA
Publication: NA
Ad#: NA

PP: Gina Bacile

PM: Ali Webb
AD: NA
ECD: NA
CD: NA
CW: NA
AE: NA

Saved: 3-5-2015 1:10 PM

Printed: 3-5-2015 1:10 PM
Print Scale: None
Printer: Abbott
Media: Print
Type: Magazine
Vendor: None

89981.3M

INKS:
Cyan
Magenta
Yellow
Black

SO5#:
Client: Revlon
Brand: None
Job Name: Print Ad - Full Page
JWT #: S515ADM
Campaign: Colorsilk Brunette SP
Proof: 2 Page: 1

DOC PATH: Production:Volumes:Production:REVLON:89981_HAIR_COLOR_PRINT_ADS:DOCS:89981_1M_CS_BLONDE_PAGE_AD_M3.indd

IMAGES:
89981_blonde_71_SW300_02.tif CMYK
416 ppi
72%
Up to Date
Production:REVLON:_MASTER_ART:89981_HairColor:89981_blonde_71_SW300_02.tif
89981_Packshots_GROUP_SW300_02.psd
CMYK
3243 ppi
9.25%
Up to Date
Production:REVLON:_MASTER_ART:89981_HairColor:89981_Packshots_GROUP_SW300_02.psd
LOVEISON_LOCKUP_ONWHITE_4c.ai
37.42%
Up to Date
Production:REVLON:_LOGOS:LOVEISON_LOCKUP_ONWHITE_4c.ai
FONTS:
Gotham Book, Black Type 1

INK DENSITY: None

89981_2M_CS_BURGUNDY_PAGE_AD_M4.pgs SO5 LR
03.24.2015 17:23

*89981.1*

FILE: 89981_3M_CS_BRUNETTE_PAGE_AD_M2.indd
SO5 Artist: earias
Safety: 7.75 x 10.75
Trim: 8 x 11
Bleed: 8.25 x 11.25
Gutter: None

Pub Date: NA
Publication: NA
Ad#: NA

PP: Gina Bacile

PM: Ali Webb
AD: NA
ECD: NA
CD: NA
CW: NA
AE: NA

Saved: 4-9-2015 5:52 PM

Printed: 4-9-2015 5:52 PM
Print Scale: None
Printer: Abbott
Media: Print
Type: Magazine
Vendor: None

89981.4

INKS:
Cyan
Magenta
Yellow
Black

SO5#:
Client: Revlon
Brand: None
Job Name: Print Ad - Full Page
JWT #: S515ADM
Campaign: Colorsilk Red SP
Proof: 1 Page: 1

DOC PATH: Production:Volumes:Production:REVLON:89981_HAIR_COLOR_PRINT_ADS:DOCS:89981_3M_CS_BRUNETTE_PAGE_AD_M2.indd

IMAGES:
89981_REVLON_Brun_38_SW300_02.tif
CMYK
400 ppi
75%
Up to Date
Production:REVLON:_MASTER_ART:89981_HairColor:89981_REVLON_Brun_38_SW300_02.tif
89981_Packshots_GROUP_SW300_02.psd
CMYK
3243 ppi
9.25%
Up to Date
Production:REVLON:_MASTER_ART:89981_HairColor:89981_Packshots_GROUP_SW300_02.psd
LOVEISON_LOCKUP_ONWHITE_4c.ai
37.42%
Up to Date
Production:REVLON:_LOGOS:LOVEISON_LOCKUP_ONWHITE_4c.ai
FONTS:
Gotham Book, Black Type 1

INK DENSITY: None

89981_1M_CS_BLONDE_PAGE_AD_M3.pgs SO5 LR
03.05.2015 13:05

*89981.3M*

FILE: 89981_4M_CS_RED_PAGE_AD_M1.indd
SO5 Artist: David Cohen
Safety: 7.75 x 10.75
Trim: 8 x 11
Bleed: 8.25 x 11.25
Gutter: None

Pub Date: NA
Publication: NA
Ad#: NA

PP: Gina Bacile

PM: Ali Webb
AD: NA
ECD: NA
CD: NA
CW: NA
AE: NA

Saved: 3-26-2015 1:43 PM

Printed: 3-26-2015 1:43 PM
Print Scale: None
Printer: Abbott
Media: Print
Type: Magazine
Vendor: None

INKS:
Cyan
Magenta
Yellow
Black

DOC PATH: Production:Volumes:Production:REVLON:89981_HAIR_COLOR_PRINT_ADS:DOCS:89981_4M_CS_RED_PAGE_AD_M1.indd

IMAGES:
89981_red_160_SW300_01.tif
CMYK
400 ppi
75%
Up to Date
Production:REVLON:_MASTER_ART:89981_HairColor:89981_red_160_SW300_01.tif
89981_Packshots_GROUP_SW300_02.psd
CMYK
3243 ppi
9.25%
Up to Date
Production:REVLON:_MASTER_ART:89981_HairColor:89981_Packshots_GROUP_SW300_02.psd
LOVEISON_LOCKUP_ONWHITE_4c.ai
37.42%
Up to Date
Production:REVLON:_LOGOS:LOVEISON_LOCKUP_ONWHITE_4c.ai
FONTS:
Gotham Book, Black Type 1

INK DENSITY: None

89981_3M_CS_BRUNETTE_PAGE_AD_M2.pgs SO5 LR
04.09.2015 17:48

*89981.4*

INK DENSITY: None

89981_4M_CS_RED_PAGE_AD_M1.pgs SO5 X1a

03.26.2015 13:39

T:11

S:10.75

TURN ON THE POWER

O F YO U R H A I R CO LO R

B:11.25

T:11

S:10.75

TURN ON THE POWER

O F YO U R H A I R CO LO R

B:11.25

T:11

S:10.75

TURN ON THE POWER

O F YO U R H A I R CO LO R

B:11.25

T:11

S:10.75

B:11.25

TURN ON THE POWER

O F YO U R H A I R CO LO R

2015 Revlon

T:8
S:7.75

2015 REVLON INC.

T:8
S:7.75

Portfolio
Print Production
Bleed: 8.75"
Trim: 7.875"

Bleed: 9.25"

Live: 7"

Trim: 7.875"

B:9.25

B:8.25

Bleed: 9.25"

Bleed: 8.75"

T:8.75

T:7.875

Trim: 7.875"

Trim: 7.875"

S:8.25

Live: 7"

S:7

Safety: 7"

T:10.5

Live: 10"

Trim: 10.5"

Bleed: 11.25"

Trim: 10.5"

Safety: 9.875"

Bleed: 11.125"

Safety: 9.5"

Trim: 10.75"

S:9.75

TAILOR YOUR FALL FASHION

AROUND SOMETHING TIMELESS

B:11.125

Bleed: 11.25"

T:10.875

Live: 10"

come rain or
come shine.
Tis year,
make it shine.

S:10.125

Trim: 10.5"

Shell love you

B:11.125

SLIP INTO SOMETHING

TIMELESS THIS SEASON
PREVIEW THE LATEST DIAMOND RIGHT HAND
RING DESIGNS AT ADIAMONDISFOREVER.COM

Bleed: 11.25"

Everlon is a trademark used under license from the De Beers Group of Companies

Safety: 7"

PREVIEW THE LATEST DIAMOND RIGHT HAND

RING DESIGNS AT ADIAMONDISFOREVER.COM

TAILOR YOUR SPRING FASHION

AROUND SOMETHING TIMELESS.
THE RIGHT HAND RING.
Everlon TM is a trademark used under license from the De Beers Group of Companies

PREVIEW THE LATEST DESIGNS

AT ADIAMONDISFOREVER.COM

THIS SPRING SLIP ON

SOMETHING TIMELESS.
THE RIGHT HAND RING.
PREVIEW THE LATEST DESIGNS
AT ADIAMONDISFOREVER.COM
The Forevermark is used under license. From top to bottom: Daniel K, Martin Katz, Catherine Angiel, Mia & Kompany, Kwiat.

The Forevermark is used under license. From left to right: H. Stern, Lorraine Schwartz, Susan Rosen, Munnu The Gem Palace, Renee Lewis

The Forevermark is used under license. From top to bottom: Andin International, Vera Wang Fine Jewelry, Michael Beaudry, S&J Diamond Corporation, Andrew Fox, Hansa Diamonds.

VISIT ADIAMONDISFOREVER.COM TO VIEW NEW

DESIGNS AND LOCATE AN OFFICIAL EVERLON RETAILER.

The Forevermark is used under license. From top to bottom: Unique Designs, The Stuckey Co., Andin International, RAND Diamond, Hearts on Fire, Andrew Fox.

The Forevermark is used under license. From top to bottom: Daniel K, Martin Katz, Catherine Angiel, Mia & Kompany, Kwiat.
The Forevermark is used under license. From left to right: H. Stern, Lorraine Schwartz, Susan Rosen, Munnu The Gem Palace, Renee Lewis

Ad No. 5576A
RHR - Hanger
P4CB
Bleed: 9.25'' x 11.125''
Trim: 7.875'' x 10.5''
Live: 7'' x 9.875''
J. Walter Thompson, NY 2007
Job No. DB-RHR-M75576
CD: Walt Connelly
AD: Mary Warner
CW: Claire Morrissey
AE: Natalie Nymark
AB: Cassandra Halloran
PP: Lauren Eberhardt
PM: Lynda Chambara
EPS# 64480
In Style, Vogue, People Style, Us Weekly
April, 2007

The Forevermark is used under license. From top to bottom: Unique Designs, The Stuckey Co., Andin International, RAND Diamond, Hearts on Fire, Andrew Fox.

Ad No. M6323A
2006 Right Hand Ring Hook
Page 4/C Bleed
Bleed: 8-3/4'' x 11-1/4''
Trim: 7-7/8'' x 10-1/2''
Live: 7'' x 10''
JWT, New York 2006
Job No. DB-BAF-M65150
CD: Walt Connelly/Toby Barlow
AD: Phil Kelly
CW: Dinesh Kapoor
AE: Natalie Nymark
AB: Cassandra Halloran
PP: Linda Herskovic
PM: Marie Palomeque
EPS# 59247
Consumer Pubs - 11/06
DOC: 59247_M6323A.qxp

AD#: M6323A

EPS #: 59247

JOB#: DB BAF M65150

BLEED: 8.75" x 11.25"

TRIM: 7.875" x 10.5"

SAFETY: 7" x 10"

GUTTER:

OPERATOR: L. Stout

PREV OP: L. Stout

PROOF#: 8 to FTP

PAGE#: 1

SAVED: 12/5/06 - 5:43 PM

PRINTED: 7/26/06 - 6:02 PM

PRINTED FROM COLLECTED FILE WITH

HI RES ART SENT VIA FTP

COLLECTED TO DESKTOP
WITH HIRES ART
FOR FTP TRANSFER
Ad No. 5568A
RHR April Books PIN CUSHION
P4CB
Bleed: 9.25''w x 11.25''h
Trim: 7.875''w x 10.75''h
Live: 7''w x 9.5''h
JWT, NY 2007
Job No. DB-RHR-M75568
CD: Walt Connelly
AD: Mary Warner
CW: Claire Morrissey
AE: Natalie Nymark
AB: Cassandra Halloran
PP: Lauren Eberhardt
PM: Lynda Chambara
EPS# 64477
Self, Shape, Glamour, Cosmo,
Marie Claire April 2007

DOC PATH: EPS_PRODUCTION:Production:EPS_PROD_MECHANICALS:2006:07 WIP July 06-1:DTC:59247_RHR 2006:59247

Documents:59247_M6323A.qxp
IMAGES: Forevermark_73k.eps @ 15.4%, ADIF_bluegrey_rhr06r1.eps @ 100%, RHR_Hook_062606.v5p1.eps @ 80%
FONTS: Laudatio-Rgl-FC, Univers-U57-FC, Univers-U75-FC

DOC: 64477_5568A.qxp

AD#: 5568A

JOB#: DB-RHR-M75568

BLEED: 9.25" x 11.25"

TRIM: 7.875" x 10.75"

SAFETY: 7" x 9.5"

GUTTER:

OPERATOR: L. Stout

PREV OP: Cristina

PROOF#: 2 to disk

PAGE#: 1

SAVED: 2/21/07 - 3:52 PM

PRINTED: 2/16/07 - 3:07 PM

DOC: 64480_5576A.qxd

AD#: 5576A

EPS #: 64480

Art is hires
Legal copy 30% black

JOB#: DB-RHR-M75576

EPS #: 59247

JOB#: DB BAF M65150

SAFETY: 7" x 10"

GUTTER:

PROOF#: 7 to FTP

PAGE#: 1

OPERATOR: L. Stout

PREV OP: L. Stout

BLEED: 9.25 x 11.125

TRIM: 7.875 x 10.5

SAFETY: 7 x 9.875

GUTTER: -

SAVED: 12/5/06 - 5:41 PM

PRINTED: 7/26/06 - 6:04 PM

OPERATOR: mike_dhirani

PREV OP: L. Stout

PROOF#: INITIAL TO FTP

PAGE#: 1

DOC PATH: EPS_PRODUCTION:Production:EPS_PROD_MECHANICALS:2006:07 WIP July 06-1:DTC:59247_RHR 2006:59247

PRINTED: 2/1/07 - 7:12 PM

SAVED: 2/1/07 - 7:24 PM

DOC PATH: Macintosh HD:Users:jwt:Desktop:mikebike:02/01/2007:COLLECT:64480_5576A.qxd

IMAGES: Forevermark_68K.eps @ 15.4%, ADIF_bluegrey_rhr06r1.eps @ 100%, C15717_Ar14.eps @ 77.8%

IMAGES: Forevermark_30k.eps @ 13.5%, ADIF_KO.eps @ 100%, JWT47871_01h_02K30.tif @ 60.3%

FONTS: Laudatio-Rgl-FC, Univers-U57-FC, Univers-U75-FC

FONTS: Laudatio-Mdm-FC, Laudatio-Rgl-FC, Univers-U57-FC

COLORS: 32 23 8 16*

COLORS: 32 23 8 16*

PRINT SCALE: 100%

PRINT SCALE: 100%

PRINT SCALE: 100%

B:9 in

Pub Date:11/1/10
Publication:In Style
Ad#: 0023C

PP: Lauren Eberhardt

PM: David Watts-Miller
AD: None
ECD: Andy Clarke
CD: Rob Omodiagbe
CW: None
AE: Carolyn Jennings

Saved: 8-25-2010 8:34 PM

Printed: 8-25-2010 8:34 PM
Print Scale: None
Printer: Abbott
Media: Print
Type: Magazine
Vendor: None

INKS:
Cyan
Magenta
Yellow
Black

77530-6

SO5#:
Client: DTC
Brand: EDK
Job Name: Male Pave Ring
JWT #: 1007204
Campaign: DB - Everlon Print Revs
2010
Proof: 1 Page: 1

B:9 in

T:7.875 in

S:7 in

77530_3M_PaveRing_Rev_M2.pgs SO5 X1a

08.25.2010 20:37

T:7.875 in

S:7 in

FILE: 77530_6M_Male_PaveRing_Rev_M1.indd
SO5 Artist: L. Stout
Pub Date:12/27/10
Publication:Time, Fortune
Ad#: 0025A

Safety: 7 x 9.75
Trim: 7.875 x 10.5
Bleed: 8.25 x 11.125
Gutter: None

PP: Lauren Eberhardt

PM: David Watts-Miller
AD: None
ECD: Andy Clarke
CD: Rob Omodiagbe
CW: None
AE: Carolyn Jennings

Saved: 8-24-2010 12:16 PM

Printed: 8-24-2010 12:16 PM
Print Scale: None
Printer: Abbott
Media: Print
Type: Magazine
Vendor: None

INKS:
Cyan
Magenta
Yellow
Black

DOC PATH: Production:Volumes:Production:DTC:DTC:77530_Everlon_Love_Knots_Revs:DOCS:77530_6M_Male_PaveRing_Rev_M1.indd

IMAGES:
74879_Pave_Ring_Flare_E.tif
CMYK
320 ppi
93.57%
Up to Date
Production:DTC:_MASTER_ART:DTC:EVERLON_LOVE_KNOTS:74879_LOVEKNOTS:74879_Pave_Ring_Flare_E.tif
74879_Pave_Ring_Flare_D.tif
CMYK
320 ppi
93.57%
Up to Date
Production:DTC:_MASTER_ART:DTC:EVERLON_LOVE_KNOTS:74879_LOVEKNOTS:74879_Pave_Ring_Flare_D.tif
74879_Pave_Ring_Flare_A_01.tif CMYK
320 ppi
93.57%
Up to Date
Production:DTC:_MASTER_ART:DTC:EVERLON_LOVE_KNOTS:74879_LOVEKNOTS:74879_Pave_Ring_Flare_A_01.tif
74879_Pave_Ring_Flare_B_01.tif CMYK
320 ppi
93.57%
Up to Date
Production:DTC:_MASTER_ART:DTC:EVERLON_LOVE_KNOTS:74879_LOVEKNOTS:74879_Pave_Ring_Flare_B_01.tif
74879_Pave_Ring_Flare_F_CMYK_02.tif
CMYK
320 ppi
93.57%
Up to Date
Production:DTC:_MASTER_ART:DTC:EVERLON_LOVE_KNOTS:74879_LOVEKNOTS:74879_Pave_Ring_Flare_F_CMYK_02.tif
74879_Pave_Ring_Flare_C.tif
CMYK
320 ppi
93.57%
Up to Date
Production:DTC:_MASTER_ART:DTC:EVERLON_LOVE_KNOTS:74879_LOVEKNOTS:74879_Pave_Ring_Flare_C.tif
74879_Pave_Ring_CMYK_12_ALT.tif
CMYK
1459 ppi
20.56%
Up to Date
Production:DTC:_MASTER_ART:DTC:EVERLON_LOVE_KNOTS:74879_LOVEKNOTS:74879_Pave_Ring_CMYK_12_ALT.tif
EVERLON_logo_KO.ai
33.48%
Up to Date
Production:DTC:_LOGOS:EVERLON_LOVE_KNOTS:EVERLON_logo_KO.ai
FONTS:
Gill Sans Regular Type 1
B:9.25 in
Adobe Caslon Pro Semibold, Regular
OpenType

INK DENSITY: None

B:9 in

T:7.875 in

S:7 in

Safety: 8.25 x 10.125

Trim: 8.75 x 10.875
Bleed: 9.25 x 11.125
Gutter: None

*77530-3*

B:9 in

T:7.875 in

FILE: 77530_3M_PaveRing_Rev_M2.indd
SO5 Artist: Jay Green

DOC PATH: Production:Volumes:Production:DTC:DTC:77530_Everlon_Love_Knots_Revs:DOCS:77530_3M_PaveRing_Rev_M2.indd

IMAGES:
74470_Pave_Ad_Ligter_SW300_29.tif
CMYK
595 ppi
50.38%
Up to Date
Production:DTC:_MASTER_ART:DTC:EVERLON_LOVE_KNOTS:74470_LOVEKNOTS:74470_Pave_Ad_Ligter_SW300_29.tif
EVERLON_tagline_TM_KO.ai
27.73%
Up to Date
Production:DTC:_LOGOS:EVERLON_LOVE_KNOTS:EVERLON_tagline_TM_KO.ai
EVERLON_logo_KO.ai
37.53%
Up to Date
Production:DTC:_LOGOS:EVERLON_LOVE_KNOTS:EVERLON_logo_KO.ai
FONTS:
Gill Sans Regular Type 1

Documents:59247_M6324A.qxp

FONTS: Laudatio-Rgl-FC, Univers-U57-FC

COLORS: 32 23 8 16*

S:7 in

77530-3

SO5#:
Client: DTC
Brand: EDK
Job Name: Female Pave Ring
JWT #: 1007204
Campaign: DB - Everlon Print Revs
2010
Proof: 2 Page: 1

Logo/blue type: 32c 23m 8y 16k

(some characters lighter % of this color)
Legal: 57k-73k (characters lighter on light bkgd area)

AD#: M6324A_ALT
TRIM: 7.875" x 10.5"

IMAGES: ADIF_KO.eps @ 100%, Forevermark_60k.eps @ 15.4%, JWT47872_01h_02K30.tif @ 60%*

T:7.875 in

Color usage:

DOC: 59247_M6324A.qxp

DOC PATH: S05_PRODUCTION:Production:EPS_PROD_MECHANICALS:2007:02 WIP February 07-1:DTC:64477_RHR

VISIT ADIAMONDISFOREVER.COM TO VIEW NEW

DESIGNS AND LOCATE AN OFFICIAL EVERLON RETAILER.

UPDATED WITH DOCUMENT/ART

FROM ENGRAVER 8.15.06

BLEED: 8.75" x 11.25"

Pincushion:64477_Documents:64477_5568A.qxp

B:9 in

COLORS: 32 23 8 16*
PRINT SCALE: 100%

EPS #: 64447

Ad No. M6324A
2006 Right Hand Ring Shears
Page 4/C Bleed
Bleed: 8-3/4'' x 11-1/4''
Trim: 7-7/8'' x 10-1/2''
Live: 7'' x 10''
JWT, New York 2006
Job No. DB-BAF-M65150
CD: Walt Connelly/Toby Barlow
AD: Phil Kelly
CW: Dinesh Kapoor
AE: Natalie Nymark
AB: Cassandra Halloran
PP: Linda Herskovic
PM: Marie Palomeque
EPS# 59247
Consumer Pubs - 11/06

T:9 in

*77530-6*

S:7 in

S:8.25 in

INK DENSITY: None

every greAt

Yellow,

Black

COlOrS:

Cyan,

Magenta,

Yellow,

Black

DOC PATh: P
roduction:Volumes:Production:DTC:SEIZE_THE_DAY:XMAS_PRINT_09:68208_09_XMAS_PRINT:DOCS:68208_4_7643A_
r1.indd

ImAGeS: Forevermark_rev.eps, ADIF_KO.eps, CircNeck_MAG_091806.v2.tif (1211 ppi; CMYK; 99.08%)

FONTS: Times (Regular), Sackers Gothic (Light), Perpetua MT (Titling MT Light)

Ad No: 7643A
SO5#:
68208-4
Client: DTC
media: P4CB
JOB#:
DB-XMS-M75907
Bleed: 9 in x 11.125 in
Trim: 7.875 in x 10.5 in
Safety: 7 in x 9.687 in
Pub:
Robb Report - 12/1/07

eCD: CD: Walt Connelly
AD: Rob Omodiagbe
CW: Ae: Lauren Rodwell
PP:
Lauren Eberhardt
Pm: Marie Palomeque
JWT, NY 2007

COlOrS:

Cyan,

Magenta,

Yellow,

Bleed:
9 in x 11.125 in
Artist:
LStout
Trim:
7.875 in x 10.5 in
Prev Artist: JKolodny
Safety:
7 in x 9.687 in
Print Scale: None
Gutter:
None
File Name: 68208_6_7641A_r1.indd

Black

DOC PATh: P
roduction:Volumes:Production:DTC:SEIZE_THE_DAY:XMAS_PRINT_09:68208_09_XMAS_PRINT:DOCS:68208_6_7641A_
r1.indd

ImAGeS: Forevermark_rev.eps, ADIF_KO.eps, Earings_MAG_091806.v2.tif (1277 ppi, 1284 ppi; CMYK; 93.93%, 93.43%)
FONTS: Times (Regular), Sackers Gothic (Light), Perpetua MT (Titling MT Light)

the forevermark is used under license.

the forevermark is used under license.

the forevermark is used under license.

SO5#:
68208-6
Saved:
9/28/07 2:04 PM
Ad#:
7641A
Printed: 9/28/07 2:04 PM

Job #: DB-XMS-M75907 Proof:
2
Program: InDesign 4.0.2 Page:
1
Client:
DTC

Product:
XMS

forever.

beginning

Ad No: 7641A
SO5#:
68208-6
Client: DTC
media: P4CB
JOB#:
DB-XMS-M75907
Bleed: 9 in x 11.125 in
Trim: 7.875 in x 10.5 in
Safety: 7 in x 9.687 in
Pub:
Money - 12/1/07

eCD: CD: Walt Connelly
AD: Rob Omodiagbe
CW: Ae: Lauren Rodwell
PP:
Lauren Eberhardt
Pm: Marie Palomeque
JWT, NY 2007

SO5#:
68208-7
Saved:
9/28/07 2:05 PM
Ad#:
7640A
Printed: 9/28/07 2:05 PM

Job #: DB-XMS-M75907 Proof:
2
Program: InDesign 4.0.2 Page:
1
Client:
DTC

Product:
XMS
COlOrS:

Cyan,

Magenta,

Yellow,

Bleed:
9 in x 11.125 in
Artist:
LStout
Trim:
7.875 in x 10.5 in
Prev Artist: JKolodny
Safety:
7 in x 9.687 in
Print Scale: None
Gutter:
None
File Name: 68208_7_7640A_r1.indd

Black

DOC PATh: P
roduction:Volumes:Production:DTC:SEIZE_THE_DAY:XMAS_PRINT_09:68208_09_XMAS_PRINT:DOCS:68208_7_7640A_
r1.indd

ImAGeS: Forevermark_rev.eps, ADIF_KO.eps, PrincStud_MAG_091906_v4.tif (672 ppi; CMYK; 51.84%)

FONTS: Times (Regular), Sackers Gothic (Light), Perpetua MT (Titling MT Light)

S:10 in

Magenta,

FONTS: Times (Regular), Sackers Gothic (Light), Perpetua MT (Titling MT Light)

required

Battery life ?

Ad No: 7640A
SO5#:
68208-7
Client: DTC
media: P4CB
JOB#:
DB-XMS-M75907
Bleed: 9 in x 11.125 in
Trim: 7.875 in x 10.5 in
Safety: 7 in x 9.687 in
Pub:
Mens Journal - 12/1/07

eCD: CD: Walt Connelly
AD: Rob Omodiagbe
CW: Ae: Lauren Rodwell
PP:
Lauren Eberhardt
Pm: Marie Palomeque
JWT, NY 2007

SO5#:
68208-8
Saved:
9/28/07 2:05 PM
Ad#:
7647A
Printed: 9/28/07 2:05 PM

Job #: DB-XMS-M75907 Proof:
2
Program: InDesign 4.0.2 Page:
1
Client:
DTC

Product:
XMS
COlOrS:

Cyan,

Magenta,

Yellow,

Bleed:
9.25 in x 11.25 in
Trim:
9 in x 10.75 in
Safety:
8.25 in x 10 in
Gutter:
None

Artist:
LStout
Prev Artist: lstout
Print Scale: None

File Name: 68208_8_7647A_r1.indd

Black

DOC PATh: P
roduction:Volumes:Production:DTC:SEIZE_THE_DAY:XMAS_PRINT_09:68208_09_XMAS_PRINT:DOCS:68208_8_7647A_
r1.indd

ImAGeS: SqNeck_MAG_091906.v4.tif (1233 ppi; CMYK; 48.57%), Forevermark_rev.eps, ADIF_KO.eps

FONTS: Times (Regular), Perpetua MT (Titling MT Light), Sackers Gothic (Light)

Ad No: 7647A
SO5#:
68208-8
Client: DTC
media: P4CB
JOB#:
DB-XMS-M75907
Bleed: 9.25 in x 11.25 in
Trim: 9 in x 10.75 in
Safety: 8.25 in x 10 in
Pub:
Trader Monthly, Best Life - 12/1/07

eCD: CD: Walt Connelly
AD: Rob Omodiagbe
CW: Ae: Lauren Rodwell
PP:
Lauren Eberhardt
Pm: Marie Palomeque
JWT, NY 2007

B:11.25 in

Cyan,

ImAGeS: Forevermark_rev.eps, ADIF_KO.eps, BambooRing_MAG_091906_v3.tif (901 ppi; CMYK; 133.04%)

has no end
but it has a

T:10.75 in

Bleed:
9 in x 11.125 in
Artist:
LStout
Trim:
7.875 in x 10.5 in
Prev Artist: JKolodny
Safety:
7 in x 9.687 in
Print Scale: None
Gutter:
None
File Name: 68208_4_7643A_r1.indd

T:10.5 in

SO5#:
68208-4
Saved:
9/28/07 2:02 PM
Ad#:
7643A
Printed: 9/28/07 2:02 PM

Job #: DB-XMS-M75907 Proof:
2
Program: InDesign 4.0.2 Page:
1
Client:
DTC

Product:
XMS

S:9.687 in

COlOrS:

DOC PATh: P
roduction:Volumes:Production:DTC:SEIZE_THE_DAY:XMAS_PRINT_09:68208_09_XMAS_PRINT:DOCS:68208_2_7645A_
r1.indd

Ad No: 7645A
SO5#:
68208-2
Client: DTC
media: P4CB
JOB#:
DB-XMS-M75907
Bleed: 9 in x 11.125 in
Trim: 7.875 in x 10.5 in
Safety: 7 in x 9.687 in
Pub:
Mens Health - 12/1/07

eCD: CD: Walt Connelly
AD: Rob Omodiagbe
CW: Ae: Lauren Rodwell
PP:
Lauren Eberhardt
Pm: Marie Palomeque
JWT, NY 2007

no tech support

B:11.125 in

FONTS: Times (Regular), Sackers Gothic (Light), Perpetua MT (Titling MT Light)

Bleed:
9 in x 11.125 in
Artist:
LStout
Trim:
7.875 in x 10.5 in
Prev Artist: LStout
Safety:
7 in x 9.687 in
Print Scale: None
Gutter:
None
File Name: 68208_2_7645A_r1.indd

T:10.5 in

Black

ImAGeS: Forevermark_rev.eps, 3SRing_MAG_091906_v5.tif (1011 ppi; CMYK; 118.59%), ADIF_KO.eps

SO5#:
68208-2
Saved:
9/28/07 1:59 PM
Ad#:
7645A
Printed: 9/28/07 1:59 PM

Job #: DB-XMS-M75907 Proof:
2
Program: InDesign 4.0.2 Page:
1
Client:
DTC

Product:
XMS

S:9.687 in

to be remembered

forever

B:11.125 in

something to wear.

Ad No: 7646A
SO5#:
68208-1
Client: DTC
media: P4CB
JOB#:
DB-XMS-M75907
Bleed: 9 in x 11.125 in
Trim: 7.875 in x 10.5 in
Safety: 7 in x 9.687 in
Pub:
Esquire

eCD: CD: Walt Connelly
AD: Rob Omodiagbe
CW: Ae: Lauren Rodwell
PP:
Lauren Eberhardt
Pm: Marie Palomeque
JWT, NY 2007

T:10.5 in

Yellow,

shell need

AND No eND.

Bleed:
9 in x 11.125 in
Artist:
LStout
Trim:
7.875 in x 10.5 in
Prev Artist: JKolodny
Safety:
7 in x 9.687 in
Print Scale: None
Gutter:
None
File Name: 68208_1_7646A_r2.indd

S:9.687 in

Magenta,

memory card

A miDDle

B:11.125 in

Cyan,

T:10.5 in

is a long time.

for this christmas

DOC PATh: P
roduction:Volumes:Production:DTC:SEIZE_THE_DAY:XMAS_PRINT_09:68208_09_XMAS_PRINT:DOCS:68208_1_7646A_
r2.indd

S:9.687 in

COlOrS:

you Wont need a

B:11.125 in

T:10.5 in

S:9.687 in

HAS A begiNNiNg,

SO5#:
68208-1
Saved:
9/28/07 1:56 PM
Ad#:
7646A
Printed: 9/28/07 1:56 PM

Job #: DB-XMS-M75907 Proof:
1
Program: InDesign 4.0.2 Page:
1
Client:
DTC

Product:
XMS

forever

B:11.125 in

love Story

the forevermark is used under license.

the forevermark is used under license.

the forevermark is used under license.

77530_6M_Male_PaveRing_Rev_M1.pgs SO5 X1a

08.24.2010 12:20

Portfolio
Digital Production

Digital Production for Advertising and Marketing. I oversee the production of iPad, tablet,
and mobile ads. Gif animated and static web banners, email banners, and creative development work for mobile apps and websites.

COM

ACT

SCI-

COM

FI

ON
COM

SCI-FI

EDY
SCI-

ACTI

FI

PLAY NOW

EDY

PLOT
PARTY
THROW A BETTER MOVIE NIGHT

SCI-

FI

PLOT
PARTY

YOUR

THROW A BETTER
MOVIE NIGHT

ION

ON

YOUR

ACTION

PLOT
PARTY

ACTI

YOUR

COMEDY

EDY

THROW A
BETTER MOVIE NIGHT

Portfolio
Digital Production

Portfolio

Portfolio

Portfolio
Contact Information:

Email: erniearias08@gmail.com
Phone: 914-294-0724
Cell: 914-217-8537

ERNIE ARIAS

95-117 Ravine Ave. Apt. LV-5D, Yonkers, NY 10701 Ph: 914-294-0724 Cell: 914-217-8537 Email: erniearias08@gmail.com
QUALIFICATIONS:

Problem solver and creative thinker. Extremely confident Studio Manager with more than 15 years in the graphic industry. Superb Print
and Digital Production, Creative Development, New Business Development, and Presentation knowledge. Managing for over 10 years,
Ive learned that every studio has its own personality and for that reason it needs its own customized directives, based on industry
standard procedures to be able to function and engage seamlessly with the rest of the agency. I also possess the ability to train, coach and
manage a team of studio artists, moving everyone up to the next level, especially when upgrading either equipment, software, or instructing
a new process. I am a big fan of procedures and technology, yet my main focus is always on our biggest asset, the human resources.

BRANDS:

As a Studio Manager, Ive worked with major leading global brands on a high volume print and digital production workflow:
Beauty & Luxury: Rolex, Este Lauder, Energizer, Revlon, Unilever; Beverages: Smirnoff, Cuervo, Beringer, Heineken, Tecate, Dos XX;
Tech & Telecom: Microsoft Bing, Nokia, Google, Vonage; Banking & Financial: HSBC, T. Rowe Price, KPMG, Merril Lynch, Bank of America;
Pharma & Food: Johnson & Johnson, Pfizer, Bristol Myers Squibb, AstraZeneca, Sunovion, Janssen, Bayer, Nestle, Special K, Kraft;
Auto Industry: Ford; Apparel & Retail: LL Bean, Puma, Macys.

WORK EXPERIENCE:
Dec 13to Present

Hogarth WorlwideStudio Manager, Production

This is quite a unique experience; WPP consolidated all its agencys production workflows under one umbrellaHogarth Worldwide.
My role here is more focused in production, and Ive found myself not just running a lean studio (JWT), but at a much larger scale (we also
provide remote studio services to other agencies, i.e., The Brand Union, SCPF, and Geometry Global). By looking at a bigger picture,
optimization is the key word at Hogarth, we move resources across the network to reduce freelancers cost and staffs downtime.

Oct 05Dec 13

J. Walter ThompsonNight Studio Manager

Assess every job coming in to the Studio, delegate assignments to the operators, maintain the workflow focused on priorities, ensure the
internal routing process follows Studio procedures, always budget-quality- and deadline-conscious. Thorough understanding of Studio
billing process and finances.
Create estimates in FileMaker Pro-Job Charge for Project Managers and Print Production Coordinators. Approve Studio artists
timesheets also using FMP.
A genuine can-do attitude, combined with a lead-by-example style have inspired my crew to become the most flexible group within the
Studio, creating a solid reputation that today serves as a role model for the whole department.
Created a proposal for a new Studio workflow and Time Management system in real time, based on barcode scanning technology.
This idea was later implemented on a new workflow system applied specifically to our file delivery unit, making our fullfillment
department even more robust and error-proof.
Working the night shift helped me to improve my decision-making skills, and the ability to troubleshoot equipment and software. It also
allowed me to be a key element on every single New Business pitch since the agency Revamp in 2005, witnessing how the agency
increased its client portfolio by getting close to 70% of New Business pitches.
Working closely with the Creative Development Studio Manager and the New Business team in scheduling and properly staffing the
Studio to support the creative during pitches and presentations.

May 02Sep 05

Sudler & HennesseyI started as a freelancer (KLK Staffing Services Agency). After 3 months in the Studio, I was offered a permanent
position and then a year later I was promoted to Studio Manager. Key player in the process of upgrading the department from being a
modest 4-Mac operator Studio to a world class, fully functional Studio with state-of-the-art software and equipment. I was also
instrumental in the creation of the Studio QC department.

Mar 00Aug 01

Tiger Information System (Staffing Services Agency)Freelancer.

JPMorgan Chase Graphic Design, Production Artist and Presentation Specialist.
Creative Network Systems (Staffing Services Agency)Freelancer.
Neuberger Bergman (financial investment firm)Graphic Design and Production Artist.
Lyons Lavey Nickel Swift (pharmaceutical advertising agency)Mac Production Artist.
Tiger Information System (Staffing Services Agency)Freelancer.
Warburg Dillon Read (financial investment firm)Graphic Design, Production Artist and Presentation Specialist.

Mar 00Jan 01
Sep 98Mar 00

Jan 97Sep 98

EDUCATION:

3G Graphics (design and pre-press Studio based in NYC)Pre-press, Typesetting and Graphic Design.

1996-1997

MacIntosh Learning Center (MLC)New York City

Graphic Specialist (course covered Quark, Photoshop, Illustrator and Mac OS)

Jul 92Dec 94

UASD (Universidad Autnoma de Santo Domingo)Santo Domingo, D.R.

5 semesters in Advertising and Marketing (Graphic Design and Illustration)

SOFTWARE:

Print and Digital Production: AdobePhotoshop, Indesign, Illustrator, Acrobat, and Bridge, Presentation: PowerPoint, Keynote;
Workflow, Billing and Digital Asset Management (DAM): Xinet, Triple Triangle (Cropster and Slugger), Dalim Twist, FileMaker Pro
(Job Charge), IBM On Demand, Smartsheet, and Hogarths proprietary tools FIDO (Workflow) and ZONZA (DAM).